Report from Annual General Meeting of Vitrolife AB (publ)

At Vitrolife’s Annual General Meeting yesterday, May 5, the following, amongst
other things, was decided:

  · The Board’s proposed dividend of SEK 1.50 per share for the financial year
2014 was approved. Thursday May 7, 2015 was adopted as the record day.

  · Re-election of Board members Fredrik Mattsson, Tord Lendau, Barbro Fridén,
Carsten Browall and Pia Marions and new election of Jón Sigurdsson, in
accordance with the election committee’s proposal. Carsten Browall was re
-elected Chairman of the Board.

  · Remuneration to the members of the Board shall be totalling SEK 1,440,000,
of which SEK 450,000 to the Chairman of the Board, SEK 150,000 to each of the
other members of the Board, SEK 60,000 to the Chairman of the Audit Committee,
SEK 60,000 to the Chairman of the Remuneration Committee and SEK 30,000 to the
other members of these committees.

  · Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 2,170,000 shares in total, corresponding to just below 10 percent of
the company’s share capital.

  · The Board was authorized to take a decision, up until the next Annual
General Meeting and on one or more occasions, with regard to the acquisition of
the company’s own shares. The Company can at no time hold more than 10 percent
of the total shares in the Company.

  · The proposed principles for remuneration and other conditions of employment
for the senior management were approved.

Gothenburg, May 6, 2015

VITROLIFE AB (publ)

The Board
Contact:

Carsten Browall, Chairman of the Board, phone +46 70 255 65 32

Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on May 6,
2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com) is an international medical device Group.
Vitrolife Fertility product area develops, produces and markets medical devices
for assisted reproduction. Work is also carried out to enable the use and
handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/